Characterization of an *Agarophyton chilense* oleoresin containing PPAR γ natural ligands with insulin-sensitizing effects in a C57BL/6J mouse model of diet-induced obesity and antioxidant activity in *Caenorhabditis elegans*.

Claudio Pinto², María Raquel Ibañez^{1,3}, Gloria Loyola^{1,3}, Luisa León^{1,3}, Yasmin Salvatore^{1,3}, Carla Gonzalez^{1,3}, Victor Barraza^{1,3}, Francisco Castañeda^{4,5,6,7}, Rebeca Aldunate⁸, Loretto Contreras-Porcía^{4,5,6,7}, Karen Fuenzalida^{*1,3}, Francisca C Bronfman^{*1,3}

*Shared corresponding authorship francisca.bronfman@unab.cl; kfuenzal@gmail.com

¹ Center for Aging and Regeneration (CARE), Department of Physiology, Faculty of Biological Sciences. Pontificia Universidad Católica de Chile. Santiago, Chile.

² Department of Cellular and Molecular Biology, Faculty of Biological Sciences. Pontificia Universidad Católica de Chile. Santiago, Chile.

³ Institute of Biomedical Sciences (ICB), Faculty of Medicine, Universidad Andres Bello. Santiago, Chile

⁴ Departamento de Ecología y Biodiversidad, Facultad de Ciencias de la Vida, Universidad Andres Bello. Santiago, Chile.

⁵ Centro de Investigación Marina Quintay (CIMARQ), Facultad de Ciencias de la Vida Universidad Andres Bello, Quintay, Chile

⁶ Center of Applied Ecology and Sustainability (CAPES), Santiago, Chile

⁷ ANID - Millennium Science Initiative Program - Instituto Milenio en Socio-ecología Costera (SECOS), Chile

⁸ Biotechnology, Faculty of Sciences, Universidad Santo Tomas. Santiago, Chile.

Abstract

The biomedical potential of the edible red seaweed *Agarophyton chilense* (former *Gracilaria chilensis*) has not been explored. Red seaweeds are enriched in polyunsaturated fatty acids and eicosanoids, which are known natural ligands of the PPAR γ nuclear receptor. PPAR γ is the molecular target of thiazolidinediones (TZDs), drugs used as insulin sensitizers to treat type 2 diabetes mellitus. TZDs medical use is limited due to undesired side effects, the fact that it has triggered the search for partial agonists without the TZDs side effects.

We produced *A.chilense* oleoresin (*Gracilex*®) that induces the activation of PPAR γ without inducing adipocyte differentiation, similar to PPAR γ partial agonists. In a model of high-fat diet-induced obesity in male mice, we showed that treatment with *Gracilex*® improves insulin sensitivity, normalizing altered glucose and insulin parameters. *Gracilex*® was enriched in palmitic acid, arachidonic acid, oleic acid, and lipophilic antioxidants such as β -carotene and tocopherols. *Gracilex*® possesses antioxidant activity in vitro (CUPRAC) and increased the antioxidant capacity *in vivo* in *Caenorhabditis elegans*. These findings support the idea that *Gracilex*® is an excellent source of healthy lipids targeting PPAR γ with antioxidant activity and a high nutraceutical value.

Key words: Natural lipids, Seaweeds, *Agarophyton chilense*, PPAR γ , insulin resistance, obesity, antioxidants, *Caenorhabditis elegans*, nutraceuticals, *Gracilex*®.

Introduction

The edible Chilean red macroalgae *Agarophyton chilense* (formerly *Gracilaria chilensis*) (1), commonly known as “pelillo”, has been used as a food and medicinal herb since pre-Hispanic times in Chile, as indicated by findings at the archaeological site of Monte Verde (~14,000 years ago) (2). *A. chilense* is distributed in New Zealand (including Chatham Island), and South America (3-6), and although this species has good nutritional potential it is mainly exploited for the extraction of the hydrocolloid agar-agar (7,8).

Seaweeds contain numerous molecules with nutritional and biomedical potential since they are rich in vitamins, minerals, essential trace elements, polysaccharides, and dietary fiber and are a good source of protein and lipids compared to terrestrial plants (9). Seaweed pigments such as carotenoids and xanthophylls have excellent nutraceutical value and show metabolic effects in humans (10). Red algae such as *A. chilense*, are an excellent source of healthy essential fatty acids such as polyunsaturated fatty acids (PUFAs), including eicosapentaenoic acid (EPA), arachidonic acid (ARA), and oleic, linoleic, and alpha-linolenic fatty acids. Other well-studied phytochemicals include fucoidans, polyphenols, tocopherols, and phytosterols. The reported bioactivities of seaweed, including antidiabetic, anti-inflammatory, antioxidant and anti-neurodegenerative activities, are varied (11,12). Thus, in recent years, there has been increased interest in identifying novel bioactive compounds that demonstrate health benefits to confirm and increase the added value to edible red seaweeds (8,13).

Various methods of extraction are used to obtain enriched fractions derived from seaweeds containing antioxidant and pigment molecules (14,15), proteins (16), polysaccharides (17) and lipids (18,19). Particularly in the *Gracilaria* genus, lipid extractions obtained by classical chloroform:methanol mixtures have revealed a complex lipid composition of glycerolipids and omega-3 and omega-6 polyunsaturated fatty acids and their oxidized derivatives, known as oxylipins (18-21). Oxylipins are synthesized either by the metabolic action of specific lipoxygenases (LOXs) or by nonenzymatic reactions on PUFAs such as EPA, ARA, linoleic acid and linolenic acid (22-24). Interestingly, the oxylipin structure is similar or equivalent to that of mammalian prostaglandins, leukotrienes, and eicosanoids (25); which are well-known ligands of peroxisome proliferator-activated receptors (PPARs) (26-28).

Lipid components of seaweeds (e.g., tocopherols, xanthophylls, carotenoids, phytosterols, PUFAs, and oxylipins) target members of the nuclear superfamily of ligand-inducible transcription factors (NRs), including peroxisome proliferator-activated receptors (PPARs), retinoid X receptors (RXRs), and the liver X receptor (LXR), which together regulate the homeostasis of cholesterol, fatty acids,

glucose, insulin sensitivity and inflammation (29,30). These studies suggest that the benefit of algae-derived food or nutraceuticals is due to their multiple targets, including NRs.

The PPARs NR subfamily present three receptor subtypes (PPAR α , PPAR β/δ , and PPAR γ) encoded by distinct genes, and they are obligate heterodimers of the RXR receptors (31). PPARs have attracted increased attention as therapeutic targets given the physiological relevance of the processes in which they are involved. These processes include lipid and glucose homeostasis, promotion of thermogenesis, lipoprotein synthesis, reduction of triglycerides, regulation of glucose levels in the blood, and the generation and maintenance of fat tissue (31-34). Additionally, PPAR activation decreases inflammatory processes by repressing proinflammatory genes regulated by NF-kappaB (35). Finally, these molecules contribute to reducing ROS (reactive oxygen species) by increasing the expression of antioxidant enzymes and increasing mitochondrial biogenesis (36). The three PPARs have natural ligands, including PUFAs and eicosanoids (37-41). All of these lipids activate PPARs with low affinity (micromolar range) compared to high-affinity synthetic agonists such as fibrates and thiazolidinediones (TZDs). In particular, fibrates, drugs used to treat dyslipidemia, target PPAR α , favoring fatty acid beta-oxidation, increasing HDL, and lowering triglyceride levels (34,42). PPAR γ has been the best-studied subtype because it is the molecular target of thiazolidinediones (TZDs), which act as full agonists of PPAR γ . These drugs were designed in the late 1990s for the treatment of type 2 diabetes mellitus (T2DM). PPAR γ is a crucial regulator of blood sugar levels, improving insulin sensitivity in patients and animal models of T2DM (43). However, in early 2007, adverse effects of these drugs, including weight gain, fluid retention, osteoporosis, heart failure, and hepatotoxicity, among others, were described (43-45). These side effects have led to restricted access in the United States and a recommendation for removal from the market in Europe and other jurisdictions (46). At the molecular level, TZDs such as rosiglitazone (RGZ) stabilize the ligand-binding site of PPAR γ in an "on" or "off" state. In contrast, partial agonists generate various dynamic and slow conformational changes by recruiting different coactivators and corepressors compared to TZDs. Of note, some partial agonists increase insulin sensitivity without adipogenic effects, such as those induced by TZDs (32,33,47,48). For instance, the partial agonist or selective PPAR γ modulator (SPPARM) INT131 has shown improvements in insulin sensitization and glycemic control in T2DM patients with minor side effects compared with those observed by treatment with the full PPAR γ agonist pioglitazone (49). In addition to synthetic SPPARMs, natural bioactive compounds with weak or partial PPAR γ affinity have shown similar properties and are effective in reducing insulin resistance (50). For example, in a rat model of diet-induced obesity, amorfrutins, a diet-derived ligand for PPAR γ , improved insulin sensitization and inflammatory and metabolic parameters (51).

T2DM is a chronic endocrine disease characterized by hyperglycemia in the blood and resistance to the action of insulin, leading to severe neurological and cardiovascular lesions, including myocardial infarction, coronary heart disease, and nonalcoholic fatty liver disease, among others. Although there are genetic risk factors, obesity is considered to explain 60-80% of diabetes cases (52-54).

There are various classes of oral drugs for glycemic management, such as biguanides (metformin), sulfonylureas (SUs), and TZDs. Currently, the first-line oral antihyperglycemic is metformin. When glucose resistance begins, metformin is used in conjunction with the patient's lifestyle as treatment (55). After metformin, SUs and TZDs are widely used, although they can cause adverse effects (see above) (56).

The majority of patients with T2DM show a deterioration in blood glucose levels over time that cannot be controlled with metformin alone. The escalation dose for metformin and SUs is limited, so patients must incorporate a second-line drug to maintain glycemic control (56,57). Recently, the use of nutraceuticals such as berberine extracts and omega-3 fatty acids has been suggested for glycemic management and dyslipidemias associated with T2DM (58). Experts have emphasized the use of nutraceuticals and functional foods to treat or mitigate T2DM due to the advantages of having a mix of molecules with simultaneous effects. The Asian continent is familiar with medicine derived from natural products. Therefore, interest in the use of nutraceuticals, including products derived from the sea, such as seaweeds (9), for the treatment of T2DM has increased (59).

Despite the rich diversity of lipids and unique phytochemical composition of red macroalgae lipids, the biomedical potential of lipids derived from *A. chilense* has not been addressed. Therefore, we started our studies by evaluating the ability of an oleoresin derived from *A. chilense* (*Gracilex*®) to activate PPAR γ . We also studied the effect of *A. chilense*-derived lipids on adipocyte differentiation and their capacity to improve the metabolic dysfunction induced by a high-fat diet (HFD). We further characterized the fatty acid profile and the antioxidant capacity of *Gracilex*® *in vitro* using a copper ion reducing antioxidant capacity (CUPRAC) assay and *in vivo* using a *Caenorhabditis elegans* model of resistance to oxidative stress. Our results indicated that *A. chilense* lipids contain PPAR γ activators that act as partial agonists since they do not induce adipocyte differentiation like RGZ. Consistently, the treatment of obese male mice (HFD) reduced glucose and insulin levels increased by HFD, without increasing adiponectin, the hormone that regulates the growth of fat tissue (60). *Gracilex*® possesses an antioxidant capacity *in vitro* and *in vivo* that correlates with high levels of tocopherols and β -carotene. Our study is the first to examine whether lipids derived from *A. chilense* have nutraceutical or biomedical applications, emphasizing the idea that *A. chilense* can be used as a source of other molecules in addition to its value as a source of agar-agar. More studies will be required to

determine the nature of the bioactive molecules present in *Gracilex*®, with particular emphasis on those that have the potential to act as SPPARM-like ligands and that show strong antioxidant activity.

2. Material and Methods

2.1 Reagents

HPLC grade dichloromethane, cyclohexane and water were purchased from Merck (Darmstadt, Germany). Cell culture reagents such as DMEM (Dulbecco's Modified Eagle Medium), RPMI 1640, opti-PRO™, GlutaMAX™ I supplement, Trypsin-EDTA 0.5% and penicillin/streptomycin were purchased from Gibco BRL (Life Technologies Inc, Gaithersburg, USA). Fetal bovine serum and horse serum were obtained from HyClone Laboratories, Inc (Thermo Fisher Scientific, MA, USA) and Lipofectamine™ 2000 from Gibco BRL (Life Technologies, MA, USA). Drugs and chemicals, such as Fmoc-Leu, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), ONPG (*ortho*-Nitrophenyl- β -galactoside), NAC (N-acetylcysteine), cell culture grade dimethyl sulfoxide (DMSO), NP-40, Oil red O, dexamethasone, isobutylmethylxanthine (IBMX) and insulin were purchased from Sigma Chemical Co. (MO, USA). Rosiglitazone and T0070907 from Cayman Chemicals (Ann Arbor, MI, USA) and INT131 was obtained from MolPort (NY, USA).

Plasmids used to measure the transcriptional activity of PPAR γ (see below) were a donation of R. M. Evans's laboratory (Howard Hughes Medical Institute, Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA, USA).

2.2 Sampling of biomass

Vegetative *A. chilense* individuals, approximately sixty centimeters in length, were collected from two areas along the Chilean coast in the Southern zone: Niebla (39.87°S 73.40°W, Los Lagos Region) and Coliumo (36.55°S 72.95°W, Biobío Region). The total biomass (20-30 kg of fresh tissue) was transported at 4° C to the laboratory, and washed with fresh water, posteriorly with 1 μ m filtered-seawater and cleaned before freezing.

2.3 Oleoresin analysis

2.3.1 *A. chilense* oleoresin production

Harvested seaweed was frozen at -20°C for two weeks and then chopped into small pieces (3-5 mm in length) by using a knife for the production of oxylipins induced by algal tissue after mechanical damage (22). Chopped alga was lyophilized to completely dry the biomass, and dried powdered seaweed was obtained after grinding in a coffee grinding machine. Dichloromethane (DCM) was used as an organic solvent for lipid extraction of pulverized dry seaweed. In brief, 50 g of pulverized dry

alga was placed in an Erlenmeyer flask with 150 mL of DCM, shaken for 30 min and filtered. The remaining sediment was extracted once again as indicated above. The whole filtered extract was evaporated, suspended in cyclohexane and lyophilized to finally obtain a lipid extraction or oleoresin of *A. chilense* (*Gracilex*®). A detailed protocol is already published in the patent application WO/2014/186913 (61).

2.3.2 Determination of total antioxidant capacity of the *A. chilense* oleoresin using a CUPRAC assay

Oleoresins obtained from dichloromethane extraction of lyophilized *Spirulina* (AquaSolar™) and Maqui (Isla Natura™) were prepared as described above for *Agarophyton chilense* extract production. The oleoresins were resuspended in DMSO, and 50 µL of sample was taken to measure the antioxidant capacity using an OxySelect™ TAC Assay kit (using the manufacturer's instructions) (Cell Biolabs, INC. CA, USA), which is based on the reduction of copper(II) to copper(I) (62). Uric acid was used as a standard to calculate the milli-equivalents of antioxidant.

2.3.3 Analysis of lipid and antioxidant contents of *A. chilense* oleoresin

Six different preparations of *Gracilex*® were used to measure tocopherols (α -tocopherol, γ -tocopherol and δ -tocopherol) and β -carotene by HPLC-electrochemical methods. The fatty acid profile of *Gracilex*® was measured as fatty acid methyl esters by GC-FID. Both analyses were performed at the Center of Molecular Nutrition and Chronic Disease of Pontifical Universidad Católica according to the Chilean normative procedure NCh2550-ISO5508.

2.4 Cellular studies

2.4.1 Cell lines

HeLa, PC12 and 3T3-L1 cell lines were obtained from the American Type Culture Collection (ATCC; Manassas, USA). All the cells were cultured following ATTC recommendation in a 5% CO₂ incubator at 37°C and 95% humidity.

PC12 cells were grown and cultured in RPMI 1640 medium supplemented with 10% horse serum (HS), 5% fetal bovine serum (FBS) and antibiotic/antimycotic (Ab-Am). HeLa cells were grown and cultured in DMEM high glucose with 10% FBS and penicillin/streptomycin, and 3T3-L1 cells were grown and cultured in DMEM high glucose with 10% fetal calf serum (FCS) and P/S. These cells were grown under low passages and at a maximum of 70% confluence.

2.4.2 Cellular transfection

A PPAR reporter activity assay was performed by transient transfections of PC12 and HeLa cells with a reporter plasmid containing three tandem repeats of the peroxisomal proliferator response element (PPRE) fused to the herpesvirus thymidine kinase promoter upstream of the coding sequence for luciferase (PPRE-tk-LUC) and a pCMX vector containing full-length murine PPAR γ 1 (63). Cells were grown until 60–70% confluence in 24-well collagen-coated plates and transfected with 2 μ L of Lipofectamine™ 2000 (Thermo Fisher, MA, USA) and 0.3 μ g of PPRE-tk-LUC vector, 0.26 μ g of pCMX-PPAR γ vector and 0.1 μ g of β -galactosidase expression plasmid (CMV- β -Gal) (Clontech, now Takara Bio USA, Inc) vector for normalization.

HeLa cells and PC12 cells were seeded in 48-well plates at a density of 1×10^5 cells/well in 250 μ L of RPMI 1640 medium (10% HS, 5% SFB and Ab-Am) grown for 24 h and transfected with Lipofectamine 2000 (Thermo Fisher, MA, USA) with 0.8 μ g of the reporter plasmid (Gal4-dependent MH100tk-Luc), 0.8 μ g of the fusion protein plasmid (PPAR γ GAL4) and 0.053 μ g of the CMV- β -Gal as an internal control (64,65). Transfection was carried out in low serum RPMI 1640 medium (2% SFB, 2% HS) without antibiotics for 6 h, the medium was replaced, and the cells were treated with the indicated extracts and corresponding vehicle for 16 h. The medium was then discarded, and the cells were lysed with reporter lysis buffer (Cell Culture Lysis Buffer, Promega, WI, USA). The lysate was centrifuged, and the luciferase activity of the supernatant was determined using a luciferase assay system (Promega, MA, USA) and measured in a luminometer (Turner Biosystem 20/20). For normalization of luciferase activity, β -Gal activity was evaluated using o-nitrophenyl- β -D-galactopyranoside (ONPG) as the substrate in a standard colorimetric enzymatic assay. The luminescence signals obtained from the luciferase activity measurements were normalized to β -Gal colorimetric measurements to account for differences in the transfection efficiency or cell number. All transfection experiments were performed in triplicate.

2.4.3 Adipocyte differentiation

3T3-L1 cells were differentiated as described previously (66). Briefly, 3T3-L1 cells were seeded in DMEM with 10% FCS at a density of 6×10^5 cells/35 mm plate for lipid staining or 2×10^5 cells/12-well plate for RNA extraction. After 48 h, the differentiation medium was used; it contained freshly prepared solutions of 1 μ g/mL insulin, 0.5 mM isobutylmethylxanthine (IBMX) and 0.1 μ g/mL dexamethasone in the presence or absence of test compounds: rosiglitazone, RGZ (1 μ M), FMOC-Leu (25 μ M) or *A. chilense* oleoresin (60 μ g/mL). After 48 h, the differentiation medium was replaced with DMEM containing 1 μ g/mL insulin, and then, the medium was changed to DMEM supplemented with 10% FBS and P/S. Every 2 days the medium was changed. After 7 days of differentiation, the

cells were harvested for RNA extraction using a HiBind column (Omega Bio-Tek, GA, USA) following the manufacturer's instructions. On the 10th day of differentiation, the cells were stained with oil red O, as described previously. Briefly, the cells were washed twice with PBS at 37°C and then fixed with 4% paraformaldehyde (PFA) for 1 h at room temperature. The plate was washed with PBS and treated with 60% isopropyl alcohol for 6 min. After the plates were dried, oil red O (6:4) was added for 2 h at room temperature. Subsequently, the plates were washed extensively, dried and photographed. For quantification of oil red O incorporation in cells, the cells fixed in the plates were solubilized with pure isopropyl alcohol, and the absorbance of the solution was measured at 490 nm (67).

2.4.4 MTT viability assay

The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was performed in PC12 cells as described before with minor modifications (68). Briefly, PC12 cells were seeded in 48-well plates at a density of 1.5×10^5 cells/well in 250 μ L of RPMI 1640 medium (10% HS, 5% SFB and Ab-Am) and grown for 24 h. Then, the medium was replaced with low serum RPMI 1640 medium (2% SFB, 2% HS, Ab-Am).

3T3-L1 cells were seeded in 48-well plates at a density of 9×10^4 cells/well in 250 μ L of DMEM (10% CS and Ab-Am) and grown for 24 h. The cells were treated with the indicated extracts and the corresponding vehicle for 16 h. The cells were washed with PBS and then incubated with 0.5 mg/mL MTT dissolved in medium without phenol red or serum for 2 h at 37°C. The MTT solution was discarded, and the cells were lysed with pure DMSO. The formazan product was measured in a spectrophotometer at 570 nm and 620 nm. The difference between both measurements was used to calculate the percentage of cell survival with respect to the control.

2.4.5 RT-qPCR

RNA quality was evaluated by agarose gel integrity. Any contaminant genomic DNA was degraded by DNase treatment (RQ1, RNase-free DNase, Promega Corp., WI, USA). cDNA was generated using M-MLV reverse transcriptase (Promega Corp., WI, USA) and random primers. qPCR was performed using SYBR Green (Brilliant II SYBR Green qPCR Mastermix, Agilent Tech. CA, USA) in a Stratagene MX-3000P- qPCR System (Agilent Technologies, CA, USA). *Fabp4* (fatty acid binding 4) and *Lpl* (lipoprotein lipase) genes were amplified together with three reference genes in each run: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), NoNo and β -actin. The murine primer sequences used for *Fabp4* were F: 5'-GCGTGGATTTCGATGAAATCA-3', R: 5'-CCCGCCATCTAGGGTTATGA-3'; for *Lpl*: F: 5'-ATTTGCCCTAAGGACCCCTG-3', R: 5'-

GCACCCAACCTCTCATACATTCC-3'; for GAPDH: F: 5'-TGCACCACCAACTGCTTAGC-3', R: 5'-GGATGCAGGGATGATGTTCT-3'; for NoNo: F: 5'-TGCTCCTGTGCCACCTGGTACTC-3', R: 5'-CCGGAGCTGGACGGTTGAATGC-3' and for β -actin: F: 5'-CCTGTGCTGCTCACCGAGGC-3', R: 5'-GACCCCGTCTCCGGAGTCCATC-3'.

2.5 Mouse studies

2.5.1 Mouse treatments

Fifty adult (6 weeks old) C57BL/6J mice were imported from the Jackson Laboratory (USA). The mice were housed in a room with controlled temperature (24°C) and humidity (55%-60%) for a 12 h light/dark regime. Water and food were supplied ad libitum by Pontificia Universidad Católica de Chile Catholic University Animal Facility. All of the animal procedures were conducted in accordance with the guidelines of the Chilean National Council for Science and Technology (CONICYT).

At 6 weeks of age, the mice were separated into 5 groups of 10 animals and fed two different diets. Four groups were fed a high fat diet (HFD: 60% kcal based on fat, Research Diet, Inc., USA), and one group was fed a low-fat diet (LFD: 10% kcal based on fat) (69,70).

The animals were weighed twice a week throughout the study. At 12 weeks of age, the mice were treated as follows: the control diet (LFD) mice were treated with corn oil; the control high-fat diet (HFD) mice were treated with corn oil; the positive control HFD mice were treated with rosiglitazone (RZG) (5 mg/kg); the HFD mice were treated with two different doses of *Gracilex*®, 90 mg/kg and 300 mg/kg. The treatment was administered orally once a day by gavage for 30 days. The daily volume administered was approximately 50 μ L.

2.5.2 Measurement of plasma metabolic parameters

Blood samples were obtained at the beginning (12 weeks old) and at the end of the treatment (16 weeks old). Before sampling, the mice were fasted for 15 h. The sample was obtained by puncture of the submandibular sinus, collected in heparinized tubes, and immediately centrifuged (3500 rpm/10 min/4°C) to obtain blood plasma.

Mouse adiponectin (DuoSet® R&D Systems, USA) and mouse insulin (Ultrasensitive EIA, ALPCO Diagnostic, USA) were detected by ELISAs. Plasma levels of glucose and cholesterol were determined by using enzymatic chemical kits (Wiener Laboratories SAIC, Argentina).

2.5.3 Histopathological studies

Twelve C57BL/6J mice (12 weeks old) per experimental group were randomly assigned to one of the following treatments: corn oil (control) or *Gracilex*® (300 mg/kg). The treatment was administered orally once a day by gavage for 15 days. The daily volume administered was approximately 50 µL. At the end of the treatment, the mice were euthanized by isoflurane overdose. The liver, kidney, esophagus and stomach were extracted and maintained in 9.25% formalin (4°C) for 48 h. For the histopathological evaluation, the samples were embedded in paraffin, processed under standard conditions and stained with hematoxylin-eosin (H/E). Liver fat accumulation was determined by Sudan black staining, and liver glycogen deposition and kidney basal membrane evaluation were determined by Schiff's periodic acid (SPA) staining. The histopathological findings were classified according to magnitude (0 = absent; I = slight; II = moderate; III= severe).

2.6 *C. elegans* studies

Nematodes were raised at 20°C under standard laboratory conditions on agar plates cultured with *Escherichia coli* (OP50) as a food source (71). The oxidative stress-sensitive *msra-1(tm1421)* mutant strain (72) was used for stress resistant assays. Previously, for the oxidative stress challenge, the nematodes were fed for 24 h with *Gracilex*® or its vehicle DMSO. For administration of *Gracilex*® to the nematodes, plates were prepared as follows: *Gracilex*® was dissolved in DMSO at a concentration of 100 mg/mL. A stock of dead bacteria was prepared by growing the *E. coli* OP50 strain in LB buffer overnight. After centrifugation, the pellet was resuspended to obtain a stock concentrated 6 times. This stock was heated at 70°C for 30 min. The stock of dead bacteria was stored at -20°C until use. Twenty-five micrograms of *Gracilex*® were mixed with 50 µL of dead bacteria and NP40 (to a final concentration of 0.1%) to a final volume of 52 µL. This mix was seeded on 2 mL of NGM agar in a 35 mm plate. The plates were left to dry in the dark ON in the laminar flow chamber and stored at 4°C in the dark for no more than 1 week before use. For the oxidative stress test, L4 stage *msra-1* nematodes were grown for 24 h on plates with *Gracilex*® or DMSO (vehicle). On the day of the test, the nematodes were transferred to a 24-well plate containing 600 µL of 9 mM hydrogen peroxide dissolved in M9 medium (minimal medium containing minimal salts: KH₂PO₄, 15 g/L, NaCl, 2.5 g/L, Na₂HPO₄, 33.9 g/L, NH₄Cl, 5 g/L). Ten nematodes were placed per well, and the movement was monitored every 10 min as described in (73) until there was no living nematode (approx. 2 h). Each experiment was performed in triplicate (30 nematodes per condition) (74).

2.7 Statistical analysis

Cell-based assays for PPARγ transactivation were performed in triplicate and in at least three independent experiments. The results are expressed as the mean fold induction relative to the control condition ±SEM. One-way analysis of variance (ANOVA) followed by Tukey's multiple comparison

tests was applied to determine statistical significance between the control and treatment conditions. The same statistical tests were used for the analysis of 3T3 adipocyte differentiation in the oil ed O assay and in lipogenic gene mRNA induction determined by qPCR. For *in vivo* studies of insulin resistance, an unpaired t test was used to compare the low-fat diet group and the HFD group. For analysis of the differences between subgroups of HFD-fed mice and LFD-fed mice, one-way ANOVA and Tukey's multiple comparison tests were applied. Finally, in *C. elegans in vivo* experiments, two-way ANOVA with repeated measures was used to compare differences in the survival curves of the nematodes fed *Gracilex*® and the nematodes under control conditions. Fisher's LSD post-test was used to determine significant differences at appropriate times. Significant differences were calculated and are represented with the following symbols of significance level: * $p < 0.5$, ** $p < 0.01$, *** $p < 0.001$. Statistical analysis was performed using GraphPad Prism 5.0 for Mac (GraphPad Software, San Diego, CA, USA).

3 Results

3.1 Effect of *A. chilense* oleoresin on PPAR γ transcriptional activity

The oleoresin or lipid extract derived from *A. chilense* (*Gracilex*®) was produced as described in patent application WO/2014/186913 (61) (see methods for further details).

To determine whether *Gracilex*® can induce the transcriptional activation of PPAR γ , we used two different cell lines, HeLa and PC12, for transient transfection assays using the PPRE-TK-LUC reporter (75) cotransfected with the PPAR γ expression vector (Fig. 1A). In both cell types, the *Gracilex*® induced significant activity at 40 $\mu\text{g/mL}$, resulting in an activation of up to 65% of the maximal activation achieved by the full agonist RGZ at 1 μM . To further confirm the activation of PPAR γ by lipids derived from *A. Chilense* and to study the contribution of PPAR γ to the increased luciferase, we assessed the ability of *Gracilex*® to activate the chimeric GAL4-DBD-PPAR-LBD protein from a Gal4-dependent MH100-Luc reporter using PC12 cells (Fig. 1B). In this assay, the activation of the reporter is activated by the chimeric GAL4-DBD fusion protein, thus avoiding potential interference from any endogenous receptor (64,65). We observed dose-response activation of PPAR γ with *Gracilex*®. At a concentration of 100 $\mu\text{g/mL}$, *Gracilex*® showed PPAR γ activity induction comparable to that promoted by the SPARMs INT131 and FMOC-Leu at 25 μM (Fig. 1B). In contrast, RGZ-induced PPAR γ activation was greater than 8 times higher at 1 μM than that of *Gracilex*®, which is consistent with the definition of a full agonist (Fig. 1B). The PPAR γ activation induced by *Gracilex*® was prevented upon cotreatment with the PPAR γ antagonist T0070907 (76),

demonstrating that *A. chilense* lipids specifically activate PPAR γ (Fig. 1C). These results suggest that *Gracilex*[®] is a good source of natural ligands for PPAR γ . No effects on the survival of PC12 cells were observed for any of the *Gracilex*[®] concentrations evaluated (Supplementary Fig. 1A).

SPPARMs are selective modulators of PPAR γ activity with partial agonism and reduced side effects such as adipose tissue gain (77). Considering that PPAR γ is a master gene for adipocyte differentiation and *Gracilex*[®] activates PPAR γ similarly to SPPARM at the higher doses evaluated (60 μ g/mL and 100 μ g/mL), we next characterized the effect of *Gracilex*[®] on 3T3-L1 cells' adipocyte differentiation using a well-established protocol (66). The incubation of the 3T3-L1 cell line with RGZ (1 μ M) and a hormonal mix for seven days induced an evident increase in oil red O staining, which labels lipid droplets, indicating the accumulation of triglycerides (78). The quantification by absorbance at 490 nm of the isopropanol soluble fraction (67) derived from 3T3-L1 differentiated cells showed a twofold increase in the cells treated with RGZ compared to the cells treated with only a hormonal mixture (Fig. 2A, B). In contrast, neither FMOC-Leu nor INT131 at 25 μ M or *Gracilex*[®] at 60 μ g/mL mimicked the effects of RGZ (Fig. 2A, B). To further confirm that SPPARMs and *Gracilex*[®] do not induce adipose differentiation, we measured the induction of mRNA levels of the adipogenic marker genes *lipoprotein lipase (LPL)* and *fatty acid binding protein 4 (FABP4)*. We observed that only RGZ promoted the adipocyte differentiation program in 3T3-L1 cells (Fig. 2C). To uncover the possible toxic effects of *Gracilex*[®] in differentiated 3T3-L1 cells, we determined cell viability by the MTT assay after *Gracilex*[®], FMOC-Leu, INT131 or RGZ treatment. No changes in cell survival were found for each PPAR γ agonist in 3T3-L1 cells (Supplementary Fig. 1B). Taken together, these results indicate that *Gracilex*[®] can induce PPAR γ activation in a similar fashion to SPPARMs without promoting adipocytic differentiation or toxic effects in 3T3-L1 cells at the concentration used.

3.2 Effect of *A.chilense* oleoresin on the metabolic dysfunction caused by high-fat diet (HFD)-induced obesity in male mice

Although there are lean individuals with T2DM, obesity explains 60-80% of diabetes cases (52-54). Even though animals do not develop T2DM like humans, there are appropriate animal models for studying the effects of new natural products such as *Gracilex*[®] on the development of T2DM induced by a high-fat diet. Studies indicate that a diet high in saturated fat (and not, for example, a diet rich in sucrose) is the most appropriate for the development of metabolic dysfunction in murine models (79), imitating the physiological conditions associated with T2DM in humans, such as

insulin resistance due to failure of pancreatic cells (59). The C57BL/6J strain is a very useful strain for the development of diabetes induced by a high-fat diet (HFD) compared to other strains because it is genetically predisposed to develop obesity (69,80). This strain shows two critical characteristics of T2DM, insulin resistance and dysfunction of pancreatic beta cells. These animals are an ideal model for studying new therapeutic agents, including natural products, and their potential to modulate this condition (59). Therefore, we used this model to test the potential use of *Gracilex*® as a nutraceutical agent to improve insulin and glucose resistance induced by an HFD. Initially, we compared the body weight gain between a group of C57BL/6J mice fed an HFD and another group fed a normal diet (low fat diet, LFD). After 12 weeks, a significant difference ($p < 0.001$) in body weight was observed between the HFD and LFD groups, being 27% greater in the high caloric diet group than in the group receiving a normal diet (Fig. 3A). When we compared biochemical blood parameters in LFD vs HFD mice, a significant increase in glucose (81.7 v/s 119.5 mg/dL) (Fig. 3B) and insulin (0.29 v/s 0.62 ng/mL) (Fig. 3C) levels was observed, consistent with the insulin metabolic dysfunction. Additionally, the values of plasma adiponectin were markedly decreased (3.8 vs 1.8 μ g/mL) in the HFD mice compared to the LFD mice (Fig. 3D), confirming the parameters described in obese animals with insulin resistance. Finally, as a result of high fat intake, plasma cholesterol values increased significantly (Fig. 3E) in the HFD vs LFD mice (121 v/s 152 mg/dL). Taken together, these results indicate the effective induction of the insulin resistance state by HFD intake in mice, which is the condition required to test the effect of *Gracilex*®.

To evaluate whether possible harmful effects of *Gracilex*® ingestion may be observed in mice, we performed a histopathological study in mice treated for a shorter period of time (15 days). No major changes in the kidney and stomach were found (data not shown). In the liver, we observed moderate glycogen accumulation by PAS staining, and no changes in fat accumulation in the mice fed a normal chow diet (Supplementary Fig. 2A-D). Additionally, no changes in body weight were found (Supplementary Fig. 2E). These results suggest no toxic effects were induced by *A. chilense* oleoresin.

The HFD-treated mice were then subdivided into four groups, maintained in an HFD and orally treated for 30 days with RGZ at 5 mg/kg/day and two different *Gracilex*® doses (90 mg/kg/day, and 300 mg/kg/day) or corn oil as vehicle. After the treatment period, no variations in body weight were observed between the subgroups; however, differences between the HFD group and the LFD group were maintained (Fig. 4A), as demonstrated previously (69). The analysis of blood parameters at the end of the treatment period showed that the mice receiving the HFD and corn oil maintained a significant increase in glycemia compared with the controls (Fig. 4B). In the HFD-fed mice, the group treated with *Gracilex*® (300 mg/kg) showed a complete recovery of blood glucose levels, reaching

the levels of the LFD control mice (Fig. 4B). RGZ and *Gracilex*® (90 mg/kg and 300 mg/kg) were also able to decrease glucose to control levels (Fig. 4B). In relation to insulin parameters, the HFD mice treated with *Gracilex*® at a dose of 300 mg/kg showed a significant decrease in insulin, reaching values close to 50% of the concentrations found in the insulin-resistant HFD-treated control group (Fig. 4C). However, as expected (70,81), synthetic RGZ promoted a decrease in insulin levels, normalizing this parameter to that observed in the control LFD mice

Adiponectin levels completely recovered after 30 days of RGZ treatment in the HFD-control mice compared with the HFD-RZG mice, which was equivalent to the values measured in the LFD control group (Fig. 4D). Unexpectedly, *Gracilex*® (300 mg/kg/day) had an opposite effect compared to RGZ, and a significant reduction in adiponectin levels was found compared to that of the HFD-control mice and the HFD- *Gracilex*® (300 mg/kg) mice (Fig. 4D), which is consistent with the fact that *Gracilex*® does not induce adipocyte differentiation in 3T3L1 cells like RZG (Fig. 2). Finally, plasma cholesterol was not affected either by treatment with RGZ or with *Gracilex*® in the HFD-treated mice (Fig. 4E), and this group maintained high levels compared to those of the group of mice fed a normal diet. These data demonstrated that *A.chilense* oleoresin improves insulin sensitivity and normalizes glucose tolerance with no alterations in weight gain, despite the reduced levels of circulating adiponectin, which is an adipose tissue-derived hormone that regulates the expansion and healthy function of adipose tissue (60). According to our studies, it is possible to consider *Gracilex*® as an alternative source of natural PPAR γ ligands with similar properties found in selective PPAR modulators, presenting partial receptor activation that is sufficient for insulin sensitization in HFD-induced metabolic dysfunction with no effect on the promotion of adipocyte differentiation.

Species of the *Gracilaria* genus have already been studied in terms of lipid components by several authors, highlighting the rich and unique composition of sulfoglycolipids, polyunsaturated fatty acids, oxidized fatty acids, pigments and lipophilic antioxidant molecules (15,18,21,82,83). An overall analysis of some lipid components was performed in dichloromethane oleoresin prepared from *A. chilensis*. The *Gracilex*® fatty acid distribution is indicated in Table 1 as the relative abundance % of total fatty acid methylesters detected by gas chromatography with a flame ionization detector (GC-FID). We found a high content of saturated fatty acids ($51.4 \pm 4.89\%$), followed by polyunsaturated ($25.7 \pm 3.12\%$) and monounsaturated ($19.6 \pm 2.88\%$) fatty acids. The most abundant fatty acids were palmitic acid (C16:0), which contributed 40% of the total fatty acids analyzed; ARA (C20:4, n-6), 21.1%; oleic acid (C18:1, n-9), 14.13%; myristic acid (C15:0), 4.4%; and 4.0% of 11-octadecenoic acid (C18:1, n-7) (Table 1). In general, we found that this distribution is similar to the fatty acid

profile reported by Da costa et al. (18) in their methanolic extract of *Gracilaria* sp., a red seaweed closely related to *A. chilensis*. The omega-3 fatty acid content was low, reaching up to 1.22% of the total fatty acids analyzed. In contrast, the total content of omega-6 fatty acids was higher (Table 1). ARA is the precursor of eicosanoids and oxylipins, bioactive lipidic promoters of the defense response in seaweed (19,20). Most natural and endogenous PPAR γ ligands are derived from ARA metabolism (84); therefore, the increased abundance in this seaweed extract may account for its high PPAR γ transactivation capacity.

The nutritional value of red macroalgae is also due to the diverse content of pigments and antioxidants (14,82,85). Consequently, we determined the total antioxidant capacity (TAC) using a CUPRAC assay (cupric ion reducing antioxidant capacity) that is compatible with lipophilic antioxidants (such as tocopherols) (62) in the oleoresin of *A. chilense* and in two different botanical lipid extracts, spirulin and maqui, produced with dichloromethane extraction as *Gracilex*®. Spirulin and maqui berries are known functional foods with high nutraceutical value. Spirulin is a cyanobacteria with known antioxidant and nutritional beneficial effects (86), and maqui berry (*Aristotelia chilensis*), a flavonoid-rich berry, is well known for its antioxidant and insulin sensitizing effects (87). Table 2 shows that *Gracilex*® is slightly superior to the other botanical oleoresins, reaching a mean of 430 mg uric acid equivalent per 100 mg of oleoresin. To further explore the antioxidant molecules, we evaluated the contents of tocopherols and β -carotene in *Gracilex*®. As indicated in Table 3, we found high levels of β -carotene and tocopherols, while lycopene was not detected. The beta-carotene content was approximately 1538 μ g/g oleoresin, while the total tocopherol content was 6673 μ g/g oleoresin, which was distributed as follows in the different types of tocopherols: α -tocopherol (527.7 μ g/g), γ -tocopherol (5332.8 μ g/g), and δ -tocopherol (2660 μ g/g) and. Thus, the antioxidant capacity of *Gracilex*® is partly due to the high levels of β -carotene and tocopherols, particularly γ -tocopherol.

3.3 Antioxidant properties of *A. chilense* oleoresin.

Considering the high contents of tocopherols and β -carotene, we next assessed the ability of *Gracilex*® to confer antioxidant resistance *in vivo*. The oxidative stress-sensitive *msra-1* mutant strain of *C. elegans* (72) was chosen as a model to evaluate *in vivo* oxidative stress resistance. Since this strain has been proved to be very sensitive to acute oxidative treatment is a powerful tool to assess the physiological consequences of oxidative stress *in vivo* (88,89). Taking advantage of the autofluorescence of pigments contained in *Gracilex*®, we first evaluated whether the nematodes were able to ingest *Gracilex*® in a mixture with dead OP50 bacteria. As shown in Fig. 5A, *Gracilex*® was visualized along the digestive track of the nematodes (highlighted by red arrows), indicating that they

can ingest the *A. chilense* oleoresin. For antioxidant resistance assays, *msra-1* L4 larval stage nematodes were fed for 24 h with DMSO (CTL), *Gracilex*® or N-acetylcysteine (NAC) mixed with dead bacteria. Then, the worms were challenged with a hydrogen peroxide solution, and their movement was scored every 10 min. Fig. 5B shows the percentage of active nematodes over time after the challenge. After 80 min, 60% of the *msra-1* mutants were already inactive compared to 40% of the nematodes fed *Gracilex*®. From 70-110 min, we consistently found more active nematodes, as shown by the right shift in the survival slope, which was significant at 80 min. Similar behavior was observed in the worms that were previously exposed to NAC, a potent well-known antioxidant, at doses of 5 mM (Fig. 5C). These findings indicated that nematodes fed with *Gracilex*® extract presented increased resistance against oxidative stress, improving their survival in agreement with the CUPRAC analysis and the characterization of their antioxidant components.

4. Discussion

Interest in the study of natural bioactive molecules able to activate PPAR γ has grown over the years due to the importance of the physiological processes that these receptors regulate and to the side effects caused by pharmacological PPAR γ drugs. This interest is paralleled with an increase in the study of the biomedical potential of seaweed due to the large amounts of bioactive molecules they possess (11,90-92). The study of the lipid components of *A. chilense* and other closely related red seaweeds had demonstrated the presence of PUFAs and eicosanoids (19,22,37); however, whether the lipids present in the *Agarophyton* genus were able to activate PPAR γ and had insulin sensitizer and antioxidant effects *in vivo* was unknown. Here, we demonstrated that *A. chilense* oleoresin includes ligands that are able to activate PPAR γ with a similar level of activation to that observed with the partial PPAR γ activators FMOC-Leu and INT131. In addition, we found a beneficial effect of *Gracilex*® on insulin sensitization in a mouse model of HFD-induced metabolic disorder with a lack of some of the side effects described for the full agonist RGZ on adipose differentiation.

PPAR γ is a lipid sensor of the nutritional and metabolic status of organisms (90). As a lipid sensor, this molecule is activated by structurally diverse lipophilic substances because the PPAR γ ligand-binding pocket is the largest among the nuclear receptors, allowing the entry and binding of up to two different molecules in a covalent or noncovalent manner (93-96). Our first goal was to evaluate whether the lipids present in *A. chilense* were able to activate PPAR γ , comparing it with the full agonist rosiglitazone and with two synthetic SPPARMs, FMOC-LEU and INT131 (97,98). The magnitude of the transcriptional induction of PPAR γ achieved by *Gracilex*® was similar to that observed for SPPARM agonists, revealing, as the first finding, that *Gracilex*® possesses SPPARM-

like ligands. The fact that similar induction of PPAR γ transcriptional activity was induced in two different cell lines (Fig. 1) together with a dose-dependent response suggests that the main bioactive molecules are already present in the extract and that further modifications may not be undergone by intrinsic cell metabolism. Natural extracts presenting PPAR γ agonist activity have been reported and reviewed extensively by Wang et al. (50). In a broad screening of extracts derived from 71 different plant species, almost 40% (28 extracts) presented PPAR α or PPAR γ activity. However, whether this activity possesses insulin sensitizer activity or antioxidant activity *in vivo* was not evaluated. In agreement with our findings, a greater biological activity was found in the extracts produced with dichloromethane than in the extracts obtained with methanol (92), suggesting that the putative PPAR ligands are more easily extracted with apolar solvents. A similar screening was performed by Kim and colleagues (99) using different macroalgae and methanol/ethyl acetate extractions. They found that the extract from *Sargassum yezoense*, a brown seaweed, showed the strongest potency for PPAR γ /a transcriptional response in a PPRE-based transcriptional assay. According to their studies, the increased PPAR activity was explained by the presence of sarquinoic acids and sargahydroquinoic acids that could increase adipocyte differentiation of 3T3-L1 cells, which is an unwanted side effect for natural-derived ligands expected to be used in diabetes, since this feature is associated with weight gain in T2DM patients (100). *Gracilex*®, not only induced partial PPAR γ activation similar to SPPARMs but also improved insulin sensitivity and normalize glucose levels with no alterations in weight gain and did not promote adipocyte differentiation in a classical *in vitro* model assay.

Previously, the content of eicosanoids derived from ARA was studied in *A. chilense* and the closely related *A. vermiculophyllum*. *A. chilense* contained 8-hydroxyeicosatetraenoic acid (8-HETE) and 7,8-di-hydroxyeicosatetraenoic acid (7,8-diHETE), while *A. vermiculophyllum* contained, in addition to 8-HETE and 7,8-HETE, the prostaglandin PGE₂, which was not present in *A. chilense*. This finding suggests that closely related algae can have similar contents of PUFAs and other lipids, but different enzymes associated with their modification. The authors also found that it was possible to promote oxylin biosynthesis by subjecting the algal tissue to a mechanical damage. Physiologically, these oxylin are produced after the release of ARA by phospholipase A and conversion by lipoxygenase as defense signals against epiphytes (19,20,22,24). Our procedure for obtaining *Gracilex*® included mechanical trituration of algae to activate its intrinsic defense mechanism and subsequent extraction with DCM, suggesting that this step may increase the oxylin content of the extract. Further studies will determine if this is the case in the future. A recent analysis of the *A. chilense*'s lipids by Honda et al. (19) revealed that glycerolipids comprise the largest proportion of the total lipid contents (monogalactosyldiacylglycerol and phosphatidylcholine), carrying mostly a combination of ARA and palmitic acids (20:4n-6/16:0) in their structure. In agreement with this study, our analysis of the fatty

acid profile of *Gracilex*® showed that palmitic acid and ARA were the most abundant fatty acids, representing 40% and 21.1% of the total fatty acids, respectively. Our findings also agree with a recent report on the fatty acid profile of the related red macroalga *Gracilaria* spp. (18). The involvement of these fatty acids and metabolites in the ability of *Gracilex*® to induce PPAR γ activation is currently unknown and under investigation in our laboratory. However, it is known that among the endogenous PPAR γ ligands described in the literature, 8-HETE is characterized as a dual PPAR α and PPAR γ agonist (28,37), whereas the activity of 7,8-di-HETE has not been evaluated. Other lipid compounds present in *Gracilex*® may also act as agonists in a concerted manner, given the ability of the PPAR ligand binding pocket to bind more than one lipid agonist at the same time (26,101). PUFAs, such as ARA and docosahexaenoic acids (DHA), and their derivative eicosanoids both bind to PPAR γ , but eicosanoids are stronger agonists than PUFAs (28,102,103). Other lipids, including lysophosphatidic acids (1-O-oleyllysophosphatidic acid) (104,105) and phytanic acid (106), also possess PPAR γ transactivation activity.

One of the central pathologies in metabolic syndrome is insulin resistance, an event that occurs before T2DM. The development of this pathology directly correlates with overweight and obesity; indeed, obesity explains 60-80% of diabetes cases (107,108). Here, we provided evidence that *Gracilex*® treatment might benefit overweight patients with insulin resistance. Oral treatment of a mouse model of diet-induced obesity with *Gracilex*® improved insulin and glucose levels, which were altered by the diet. Indeed, the HFD-fed mice treated with *Gracilex*® for one month showed a notable decrease in both blood parameters and glucose and insulin levels at the 300 mg/kg dose, similar to RGZ at 5 mg/kg. RGZ increased the levels of adiponectin, as expected (109). *Gracilex*® significantly decreased the levels of adiponectin in the HFD-fed mice compared to the HFD-fed control mice. This finding indicates that the beneficial effect of *Gracilex*® is not due to the reported capacity of PPAR γ agonists to increase adiponectin levels (109). Adiponectin is a hormone that is secreted by adipose tissue and has autocrine and endocrine actions with reported global insulin sensitizer effects (60). Nonetheless, adiponectin increases the growth of fat tissue, and overexpression of adiponectin in 3T3-L1 cells increases lipid storage and adipogenesis (110). Thus, the limited capacity of *Gracilex*® to increase adipocyte differentiation and accumulation of triglycerides measured by oil red O staining in 3T3-L1 cells correlates with the decreased adiponectin levels *in vivo* induced by *Gracilex*® in the HFD-fed mice. Further experiments studying the genetic programs and transcriptomes in 3T3-L1 cells and adipose tissue from HFD-fed mice treated with vehicle and *Gracilex*® will help elucidate this issue since the *adiponectin* gene possesses PPARE and its transcription is regulated by PPAR γ (111). The regulation of adiponectin expression is tightly controlled by a number of transcription factors,

including C/EBPalpha (CCAAT/enhancer-binding protein alpha), SREBP-1c (sterol regulatory element binding protein) and CREB (cAMP response element binding protein) (112). Therefore, it is possible that lipids contained in *Gracilex*® counteract the signal pathways leading to activation of these transcription factors or that the set of coactivators recruited by the potential PPAR γ ligands present in *Gracilex*® represses adiponectin transcription since SPPARMs differentially regulate gene expression compared to TZDs (47,50).

Another mechanism for the PPAR γ effect on insulin and glucose metabolism in addition to increased adiponectin levels has been described. PPARs also generate an increase in the expression of liver enzymes regulating glycogen accumulation in the liver, which reduces the levels of glucose in the blood (113,114). Obesity downregulates PPAR γ transcriptional events that are restored by agonists, such as TZD treatment, including the promotion of adipose tissue angiogenesis and the anti-inflammatory effects on adipose tissue, decreasing systemic inflammation induced by obesity (42).

As a source of multiple types of chemical molecules, *A. chilense* oleoresin showed antioxidant activity, as has been previously reported in diverse algae-derived extracts. While aqueous extracts have been characterized in depth either for their *in vivo* activity or for their antioxidant components (such as phenols and polyphenols, amino acid-like microsporines and sulfated polysaccharides), scarce information exists for the apolar organic-produced fraction like the one we have produced in this study. In the red seaweed *Gracilaria blodgettii*, a chloroform extract could decrease the oxidative stress induced in leukocytes (115-118). These results indicate that apolar extracts can be a source of antioxidants for biological membranes.

Depending on the type of alga, the solvent used and seasonally of algae harvested, a majority or minority of antioxidant components and their activities can be redistributed between polar or apolar fractions (13,119). Difficulties in determining the *in vitro* capacity of apolar extracts or molecules through classical methods are known, and more than one assay should be used to confirm their antioxidant potential (120,121). Considering the few alternative methods for determining antioxidant capacity in oleoresins, in addition to the *in vitro* TAC method, we evaluated the *in vivo* antioxidant capacity of *Gracilex*® using a strain mutant of *C. elegans* that is sensitive to oxidative stress (72). We found that nematodes fed *Gracilex*® were protected against exposure to hydrogen peroxide with a similar magnitude as that given by N-acetyl-cysteine (NAC) treatment, reflected by an increase in nematode survival. NAC is a source for the production of glutathione, and it has been shown to prevent ROS generation (89) and to increase oxidative stress protection in *C. elegans* (88). Therefore, it is an appropriate positive control for our experiments. These results correlated with high contents

of tocopherols and β -carotene in *Gracilex*[®], which are well-known antioxidants reducing lipid peroxidation (122-124).

5. Conclusion

Altogether, our results indicate that *Gracilex*[®], an oleoresin produced from *A. chilense* after dichloromethanol extraction, contains natural PPAR γ ligands that increase its transcriptional activity, with insulin sensitizing and antioxidant properties *in vivo*.

Figure Legends

Figure 1. *A. chilense* oleoresin induces PPAR γ transcriptional activation.

Two different cell-based reporter assays to measure PPAR γ activation were performed. (A) Left panel, schematic representation of vectors used for cotransfection. PC12 and HELA cells were cotransfected with plasmids expressing full-length murine PPAR γ and a reporter plasmid containing PPRE elements driving the expression of luciferase, together with a plasmid expressing beta-galactosidase as a transfection control. The full PPAR γ agonist rosiglitazone (RGZ, 1 μ M) and the *A. chilense* oleoresin or *Gracilex*[®] (*AgEx*, 40 μ g/mL) induce the transcriptional activation of PPAR γ , as shown by the increased luciferase activity and normalized to beta-galactosidase expression (expressed as relative PPAR γ activity).

In PC12 cells (n=3) and HeLa cells (n=6-13), the treatments (RGZ and *AgEx*) were compared to control transfected cells (DMSO), and the values are presented as $\pm$ SEM, ** $p < 0.01$ *** $p < 0.001$ (one-way ANOVA, Tukey's post hoc test). (B) Left panel, schematic representation of vectors used for cotransfection. A plasmid with expression of a chimeric construct of the PPAR γ ligand binding domain (PPAR γ LBD) gene and the DNA binding domain of Gal4 (Gal4LBD) was cotransfected with the response element of GAL4 (REGal4) driving the expression of luciferase. As in A, a third plasmid was included with expression of beta-galactosidase as a transfection control. Increased PPAR γ activation is expressed as relative PPAR γ activity. *AgEx* induces a dose-response activation of PPAR γ comparable to the activation induced by the selective SPPARMs of PPAR γ , FMOC-LEU and INT131 at a concentration of 25 μ M. Instead, RGZ at 1 μ M shows much higher activation (110 times over the control), as expected for a full agonist. Values are presented as $\pm$ SEM, n=3-7, *** $p < 0.001$ (left panel, one-way ANOVA, Tukey's post hoc test. Right panel, unpaired t test). (C) PC12 cells were transfected as described in B and treated with *AgEx* (60 μ g/mL) with or with the PPAR γ antagonist T0070907 (T007, 10 μ M). Values are presented as $\pm$ SEM, n=4, * $p < 0.05$ (one-way ANOVA, Tukey's post hoc test).

Figure 2. Adipogenesis in 3T3-L1 fibroblast cells is induced by rosiglitazone but

not by *A. chilense* oleoresin or by the PPAR γ SPPARMs FMOC-Leu and INT131. (A) First, 3T3-L1 preadipocytes were cultured with or without each PPAR γ agonist, FMOC-Leu and INT131 (25 μ M); RGZ (1 μ M) and *A. chilense* oleoresin or *Gracilex*[®] (*AgEx*) at 60 μ g/mL as specified in the methodology section. After 10 days of culture initiation, the cells were stained with oil red O and triglycerides, and the plates were photographed. (B) Quantification of oil red O incorporation was measured after cell lysis with isopropanol at a wavelength of 490 nm. Values are expressed as the mean relative to that of the control cells (treated with DMSO) $\pm$ SEM, n=6, *** $p < 0.001$ (one-way ANOVA, Tukey's post hoc test). (C) Effects of *AgEx* and PPAR γ agonists on the expression of lipogenic pathway-related genes during the differentiation process of mouse 3T3-L1 preadipocytes were measured after 7 days of culture initiation as indicated in the methodology section. After treatment with each compound, the cells were lysed, and the mRNA levels of the *LPL* and *FABP4*

genes were measured by qPCR. The graph shows the relative abundance compared to the control (untreated cells, control DMSO). Values are expressed as the mean relative to that of the control cells (treated with DMSO) $\pm$ SEM, $n=4$, $**p<0.01$, $***p<0.001$ (one-way ANOVA, Tukey's post hoc test).

Figure 3. Promotion of weight gain and glucose and insulin resistance in male C57BL/6J mice administered a high-fat diet (HFD). Six-week-old mice were treated for an additional 6 weeks with a low-fat diet (LFD, $n=20$) and HFD ($n=40$). (A) Weight recording in groups of mice given an LFD and HFD after six weeks of treatment. During the whole period, the weights were recorded twice a week. Values are expressed as the mean recorded weight $\pm$ SEM, $***p<0.001$ (unpaired t test). (B-E) Biochemical blood parameters were measured in both groups: plasma glucose (mg/dL) (B), plasma insulin (ng/mL) (C), plasma adiponectin (μ g/mL) (D), and plasma cholesterol (mg/dL) (E). Values are expressed as the mean $\pm$ SEM, and significant differences are highlighted between the LFD vs HFD group $**p<0.01$, $***p<0.001$ (unpaired t test).

Figure 4. *A. chilense* oleoresin improves altered glucose and insulin parameters in the plasma of the male C57BL/6J mice given an HFD.

After 6 weeks of LFD and HFD treatments as indicated in Fig. 3, LFD mice continued with the same diet with additional daily treatment with approximately 50 μ L of corn oil (vehicle of drugs) for one month (30 days). The HFD-treated mice were divided into 4 groups, and they continued with the same diet, but 4 different daily treatments were given: corn oil (vehicle), 90 and 300 (mg/kg) of *A. chilense* oleoresin or *Gracilex*[®] (*AgEx*) and RGZ (5 mg/kg). During the whole period, the weights were recorded twice a week. (A) Comparison of weights at the beginning and at the end of the treatment for each group. Values are expressed as the mean $\pm$ SEM, $n=10$, $***p<0.001$ (one-way ANOVA, Tukey's post hoc test). (B-E), After the treatment, the mice were fasted for 15 h before taking blood samples, and plasma glucose (mg/dL) (B), plasma insulin (ng/mL) (C), plasma adiponectin (μ g/mL) (D), and plasma cholesterol (E) (mg/dL) are shown.

Values are expressed as the mean $\pm$ SEM, $n=10$. Significant differences are highlighted between the LFD and HFD groups (left panels $**p<0.01$, $***p<0.001$, unpaired t test). Significant differences found in post-treatment experiments in the HFD group are regarding their HFD control. $*p\leq 0.05$; $**p<0.01$ $***p<0.001$ (one-way ANOVA, Tukey's post hoc test).

Figure 5. *A. chilense* oleoresin increases oxidative stress resistance in *C. elegans* challenged with hydrogen peroxide. (A) Representative illustration of a whole *C. elegans* organism extracted from Corsi A. K and cols., 2015 (125). Red autofluorescence of the extract was observed along the nematode digestive track visualized under fluorescence microscopy. *A. chilense* oleoresin or *Gracilex*[®] (*AgEx*) was dissolved in DMSO, mixed with 25 μ L of dead bacteria and dispersed on 1.5 mL of agar. The white arrow shows the nematode pharynx. The red arrow highlights the fluorescent extract inside the nematode. Control corresponds to an adult N2 worm grown under standard conditions. (B) L4 stage nematodes from the *msra-1* strain were fed *AgEx* for 24 h and then exposed to oxidative stress by 9 mM hydrogen peroxide for up to 110 min. Values are expressed as the mean ($n=5$) percentage of survival $\pm$ SEM, $**p<0.01$ (two-way ANOVA with repeated measures and Fisher's LSD test). (C) The same experimental assay was performed as described in B, but nematodes were fed two different concentrations (1 mM and 5 mM) of N-acetylcysteine (NAC). NAC was used as a positive control. Values are expressed as the mean ($n=3$) percentage of survival $\pm$ SEM, $**p<0.01$ and $***p<0.001$ (two-way ANOVA with repeated measures and Fisher's LSD test). Significant differences in the percentage of active nematodes were found under treatment with 5 mM NAC compared to the control at 70, 90 and 120 min after exposure to hydrogen peroxide.

Supplementary Figure 1. Cell viability of PC12 and 3T3 cells after treatment with

PPAR γ agonists and *A. chilense* oleoresin. (A) PC12 cells were cultured without or with FMOC-Leu, RGZ (1 μ M) and *A. chilense* oleoresin or *Gracilex*[®] (*AgEx*) with three different concentration 30, 60, 90 μ g/mL for 24 h. Then, the cells were incubated with MTT for 2 h at 37°C. MTT is used as an indicator of mitochondrial activity and cellular viability. The graph indicates viability relative to the control condition (treatment with vehicle, DMSO). No significant differences were found between treatments with the PPAR γ agonist and *AgEx* compared to the control (one-way ANOVA, Tukey's post hoc test). Values are expressed as the mean (n=3) $\pm$ SEM. (B) The 3T3-L1 preadipocytes were cultured without or with FMOC-Leu and INT131 at a concentration of 25 μ M, rosiglitazone (RGZ, 1 μ M) and *AgEx* (60 μ g/mL), and at the end of the differentiation period, the cells were incubated with MTT for 2 h at 37°C. The graph indicates viability relative to the control condition (treatment with vehicle, DMSO). No significant differences were found between treatments with PPAR γ agonists and *AgEx* (one-way ANOVA, Tukey's post hoc test, n=3).

Supplementary Figure 2. Histological analysis of liver and weight measurements after chronic treatment with *A. chilense* oleoresin in mice fed a normal chow diet. Three-month-old C57BL/6J mice were treated daily for 15 days with 300 (mg/kg) of *A. chilense* oleoresin or *Gracilex*[®] (*AgEx*) or corn oil (vehicle) extract. Light microphotograph of liver paraffin sections (400X). Hepatocytes were stained with periodic acidic-Schiff (PAS) staining to evaluate glycogen deposits (A and B) or with Sudan Black B staining for lipid accumulation (C and D). (A) and (C) are sections from control mice (vehicle). (B) and (D) are sections from control mice treated with *AgEx*. Mild to moderate glycogen storage was found in the group treated with *AgEx* compared to corn oil (vehicle). No difference was apparent in Sudan Black B staining between the groups. (E) Weight curves of normal chow-fed mice treated with *AgEx* for histological study. Three-month-old C57BL/6J mice were weighted 3 times per week, and after 15 days, daily treatment with *AgEx* 300 (mg/kg) or corn oil (vehicle) for an additional 15 days was started. Mice were weighted 3 times per week. The graph shows the average weight curve per group $\pm$ SEM.

Author contribution: CP, KF and FCB performed the conceptualization of the study. CP conducted the mice studies. The cell studies were performed by CP, GL, CG, YS and LL. Preparation of the *A. chilense* oleoresin was performed by CP, GL, VB, LL, RI. Availability of *A. chilense* biomass was possible by FC and LCP. VB performed CUPRAC antioxidant determination. RI and RA performed *C. elegans* studies. Supervision of experiments was performed by KF, RA, LCP and FCB. KF and FCB performed original draft preparation. Review and editing were the work of FCB, KF, LCP and RA.

Funding: Agencia Nacional de Investigación y Desarrollo (ANID) project FONDEF ID16I10185 (FCB) and Basal Center of Excellence in Science and Technology (PIA BASAL AFB170005) (FCB). CORFO "Consorcio tecnológico desarrollo sinérgico de Ingredientes Funcionales y Aditivos Funcionales IFAN" 16PTECAI-66648 (FCB and LCP).

Conflict of interest: Authors declare no conflict of interest.

Patents: The methodology to prepare the *A. chilense* oleoresin is fully described in the patent application WO/2014/186913. "Method for the preparation of an oleoresin originating from a red alga that maintains the capacity to induce the transcriptional activity of the nuclear receptor PPAR-Gamma". PCT/CL2013/000031 Pontificia Universidad Católica de Chile. Inventors: Bronfman Miguel, Bronfman Francisca, Pinto Claudio, Pissani Claudia, Paredes Martínez, María José.

References

1. Gurgel, C., Norris, J., Schmidt, W., Le, m HN., Fredericq, S. (2018) Systematics of the Gracilariales (Rhodophyta) including new subfamilies, tribes, subgenera, and two new genera, Agarophyton gen. nov. and Crassa gen. nov. *Phytotaxa* **374**, 001-023
2. Dillehay, T. D., Ramirez, C., Pino, M., Collins, M. B., Rossen, J., and Pino-Navarro, J. D. (2008) Monte Verde: seaweed, food, medicine, and the peopling of South America. *Science* **320**, 784-786
3. Bird, C. J., McLachlan, J., and Oliveira, E. C. d. (1986) Gracilaria chilensis sp.nov. (Rhodophyta, Gigartinales), from Pacific South America. *Canadian Journal of Botany* **64**, 2928-2934
4. Guillemain, M.-L., Faugeron, S., Destombe, C., Viard, F., Correa, J. A., and Valero, M. (2008) GENETIC VARIATION IN WILD AND CULTIVATED POPULATIONS OF THE HAPLOID– DIPLOID RED ALGA GRACILARIA CHILENSIS: HOW FARMING PRACTICES FAVOR ASEXUAL REPRODUCTION AND HETEROZYGOSITY. *Evolution* **62**, 1500-1519
5. Huanel, O. R., Nelson, W. A., Robitzsch, V., Mauger, S., Faugeron, S., Preuss, M., Zuccarello, G. C., and Guillemain, M.-L. (2020) Comparative phylogeography of two Agarophyton species in the New Zealand archipelago. *Journal of Phycology* **56**, 1575-1590
6. Robitzsch, V., Arakaki, N., Mauger, S., Zapata Rojas, J. C., and Guillemain, M.-L. (2019) Stranded alone: The first reported Peruvian population of Agarophyton chilensis is a single-male's clone. *Algal Research* **41**, 101527
7. Armisen, R. (1995) World-wide use and importance of Gracilaria. *J. Appl. Phycology* **7**, 231-243
8. Torres, P., Santos, J. P., Chow, F., and dos Santos, D. Y. A. C. (2019) A comprehensive review of traditional uses, bioactivity potential, and chemical diversity of the genus Gracilaria (Gracilariales, Rhodophyta). *Algal Research* **37**, 288-306
9. Wells, M. L., Potin, P., Craigie, J. S., Raven, J. A., Merchant, S. S., Helliwell, K. E., Smith, A. G., Camire, M. E., and Brawley, S. H. (2017) Algae as nutritional and functional food sources: revisiting our understanding. *Journal of Applied Phycology* **29**, 949-982
10. Mounien, L., Tourniaire, F., and Landrier, J.-F. (2019) Anti-Obesity Effect of Carotenoids: Direct Impact on Adipose Tissue and Adipose Tissue-Driven Indirect Effects. *Nutrients* **11**, 1562
11. Hafting, J. T., Craigie, J. S., Stengel, D. B., Loureiro, R. R., Buschmann, A. H., Yarish, C., Edwards, M. D., and Critchley, A. T. (2015) Prospects and challenges for industrial production of seaweed bioactives. *Journal of Phycology* **51**, 821-837
12. Ganesan, A. R., Tiwari, U., and Rajauria, G. (2019) Seaweed nutraceuticals and their therapeutic role in disease prevention. *Food Science and Human Wellness* **8**, 252-263
13. Francavilla, M., Franchi, M., Monteleone, M., and Caroppo, C. (2013) The red seaweed Gracilaria gracilis as a multi products source. *Marine drugs* **11**, 3754-3776

14. Gunathilaka, T. L., Samarakoon, K. W., Ranasinghe, P., and Peiris, L. D. C. (2019) In-Vitro Antioxidant, Hypoglycemic Activity, and Identification of Bioactive Compounds in Phenol-Rich Extract from the Marine Red Algae *Gracilaria edulis* (Gmelin) Silva. *Molecules* **24**
15. de Almeida, C. L., Falcao Hde, S., Lima, G. R., Montenegro Cde, A., Lira, N. S., de Athayde-Filho, P. F., Rodrigues, L. C., de Souza Mde, F., Barbosa-Filho, J. M., and Batista, L. M. (2011) Bioactivities from marine algae of the genus *Gracilaria*. *Int J Mol Sci* **12**, 4550-4573
16. Kazir, M., Abuhassira, Y., Robin, A., Nahor, O., Luo, J., Israel, A., Golberg, A., Livney, D. (2019) Extraction of proteins from two marine macroalgae, *Ulva* sp. and *Gracilaria* sp., for food application, and evaluating digestibility, amino acid composition and antioxidant properties of the protein concentrates. *Food Hydrocolloids* **87**, 194-203
17. Wang, X., Zhang, Z., Zhou, H., Sun, X., Chen, X., and Xu, N. (2019) The anti-aging effects of *Gracilaria lemaneiformis* polysaccharide in *Caenorhabditis elegans*. *Int J Biol Macromol* **140**, 600-604
18. da Costa, E., Melo, T., Moreira, A. S., Bernardo, C., Helguero, L., Ferreira, I., Cruz, M. T., Rego, A. M., Domingues, P., Calado, R., Abreu, M. H., and Domingues, M. R. (2017) Valorization of Lipids from *Gracilaria* sp. through Lipidomics and Decoding of Antiproliferative and Anti-Inflammatory Activity. *Mar Drugs* **15**
19. Honda, M., Ishimaru, T., Itabashi, Y., and Vyssotski, M. (2019) Glycerolipid Composition of the Red Macroalga *Agarophyton Chilensis* and Comparison to the Closely Related *Agarophyton Vermiculophyllum* Producing Different Types of Eicosanoids. *Mar Drugs* **17**
20. Weinberger, F., Lion, U., Delage, L., Kloareg, B., Potin, P., Beltran, J., Flores, V., Faugeron, S., Correa, J., and Pohnert, G. (2011) Up-regulation of lipoxygenase, phospholipase, and oxylipin-production in the induced chemical defense of the red alga *Gracilaria chilensis* against epiphytes. *J Chem Ecol* **37**, 677-686
21. Tsai, C. J., and Sun Pan, B. (2012) Identification of sulfoglycolipid bioactivities and characteristic fatty acids of marine macroalgae. *J Agric Food Chem* **60**, 8404-8410
22. Lion, U., Wiesemeier, T., Weinberger, F., Beltran, J., Flores, V., Faugeron, S., Correa, J., and Pohnert, G. (2006) Phospholipases and galactolipases trigger oxylipin-mediated wound-activated defence in the red alga *Gracilaria chilensis* against epiphytes. *Chembiochem* **7**, 457-462
23. Barbosa, M., Valentao, P., and Andrade, P. B. (2016) Biologically Active Oxylipins from Enzymatic and Nonenzymatic Routes in Macroalgae. *Mar Drugs* **14**, 23
24. Rempt, M., Weinberger, F., Grosser, K., and Pohnert, G. (2012) Conserved and species-specific oxylipin pathways in the wound-activated chemical defense of the noninvasive red alga *Gracilaria chilensis* and the invasive *Gracilaria vermiculophylla*. *Beilstein J Org Chem* **8**, 283-289
25. Di Costanzo, F., Di Dato, V., Ianora, A., and Romano, G. (2019) Prostaglandins in Marine Organisms: A Review. *Mar Drugs* **17**
26. Itoh, T., Fairall, L., Amin, K., Inaba, Y., Szanto, A., Balint, B. L., Nagy, L., Yamamoto, K., and Schwabe, J. W. (2008) Structural basis for the activation of PPARgamma by oxidized fatty acids. *Nat Struct Mol Biol*
27. Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., and Wahli, W. (1993) Fatty acids and retinoids control lipid metabolism through activation of peroxisome

- proliferator-activated receptor-retinoid X receptor heterodimers. *Proc Natl Acad Sci U S A* **90**, 2160-2164
28. Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M., and Lazar, M. A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J Biol Chem* **270**, 23975-23983
29. Bonet, M. L., Canas, J. A., Ribot, J., and Palou, A. (2015) Carotenoids and their conversion products in the control of adipocyte function, adiposity and obesity. *Arch Biochem Biophys* **572**, 112-125
30. Jalil, A., Bourgeois, T., Menegaut, L., Lagrost, L., Thomas, C., and Masson, D. (2019) Revisiting the Role of LXRs in PUFA Metabolism and Phospholipid Homeostasis. *Int J Mol Sci* **20**
31. Grygiel-Gorniak, B. (2014) Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. *Nutrition journal* **13**, 17
32. Chandra, V., Huang, P., Hamuro, Y., Raghuram, S., Wang, Y., Burris, T. P., and Rastinejad, F. (2008) Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA. *Nature* **456**, 350-356
33. Ahmadian, M., Suh, J. M., Hah, N., Liddle, C., Atkins, A. R., Downes, M., and Evans, R. M. (2013) PPARgamma signaling and metabolism: the good, the bad and the future. *Nature medicine* **19**, 557-566
34. Hong, F., Xu, P., and Zhai, Y. (2018) The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development. *Int J Mol Sci* **19**
35. Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., and Glass, C. K. (2005) A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR- γ . *Nature* **437**, 759-763
36. Fujisawa, K., Nishikawa, T., Kukidome, D., Imoto, K., Yamashiro, T., Motoshima, H., Matsumura, T., and Araki, E. (2009) TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. *Biochemical and Biophysical Research Communications* **379**, 43-48
37. Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., and Lehmann, J. M. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. *Proc Natl Acad Sci U S A* **94**, 4318-4323
38. Nagy, L., Tontonoz, P., Alvarez, J. G. A., Chen, H., and Evans, R. M. (1998) Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPAR γ . *Cell* **93**, 229-240
39. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) 15-Deoxy- $\Delta^{12,14}$ -Prostaglandin J2 is a ligand for the adipocyte determination factor PPAR γ . *Cell* **83**, 803-812
40. Yamada, H., Oshiro, E., Kikuchi, S., Hakozaki, M., Takahashi, H., and Kimura, K. (2014) Hydroxyeicosapentaenoic acids from the Pacific krill show high ligand activities for PPARs. *J Lipid Res* **55**, 895-904
41. Thuillier, P., Brash, A. R., Kehrer, J. P., Stimmel, J. B., Leesnitzer, L. M., Yang, P., Newman, R. A., and Fischer, S. M. (2002) Inhibition of peroxisome proliferator-

- activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxigenase inhibitors. *Biochem J* **366**, 901-910
42. Gross, B., Pawlak, M., Lefebvre, P., and Staels, B. (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. *Nat Rev Endocrinol* **13**, 36-49
43. Wang, S., Dougherty, E. J., and Danner, R. L. (2016) PPAR γ signaling and emerging opportunities for improved therapeutics. *Pharmacological Research* **111**, 76-85
44. Graham, D. J., Ouellet-Hellstrom, R., MaCurdy, T. E., Ali, F., Sholley, C., Worrall, C., and Kelman, J. A. (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. *JAMA : the journal of the American Medical Association* **304**, 411-418
45. Nissen, S. E. (2007) Perspective: effect of rosiglitazone on cardiovascular outcomes. *Current cardiology reports* **9**, 343-344
46. European Medicines Agency. European Medicines Agency recommended suspension of Avandia, A. a. A. (2010) (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/09/news_detail_001119.jsp).
47. Higgins, L. S., and Depaoli, A. M. (2010) Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. *The American journal of clinical nutrition* **91**, 267S-272S
48. Hughes, T. S., Chalmers, M. J., Novick, S., Kuruvilla, D. S., Chang, M. R., Kamenecka, T. M., Rance, M., Johnson, B. A., Burris, T. P., Griffin, P. R., and Kojetin, D. J. (2012) Ligand and receptor dynamics contribute to the mechanism of graded PPARgamma agonism. *Structure* **20**, 139-150
49. DePaoli, A. M., Higgins, L. S., Henry, R. R., Mantzoros, C., and Dunn, F. L. (2014) Can a selective PPARgamma modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone? *Diabetes Care* **37**, 1918-1923
50. Wang, L., Waltenberger, B., Pferschy-Wenzig, E. M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., Schuster, D., Kopp, B., Bauer, R., Stuppner, H., Dirsch, V. M., and Atanasov, A. G. (2014) Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARgamma): a review. *Biochem Pharmacol* **92**, 73-89
51. Weidner, C., de Groot, J. C., Prasad, A., Freiwald, A., Quedenau, C., Kliem, M., Witzke, A., Kodelja, V., Han, C. T., Giegold, S., Baumann, M., Klebl, B., Siems, K., Muller-Kuhrt, L., Schurmann, A., Schuler, R., Pfeiffer, A. F., Schroeder, F. C., Bussow, K., and Sauer, S. (2012) Amorphutins are potent antidiabetic dietary natural products. *Proc Natl Acad Sci U S A* **109**, 7257-7262
52. Li, J., and Lian, H. (2016) Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus : A comprehensive summary for antidiabetic drugs. *Arch Pharm Res* **39**, 731-746
53. Steffes, M. W., Sibley, S., Jackson, M., and Thomas, W. (2003) Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. *Diabetes Care* **26**, 832-836

54. Luk, A. O., Lau, E. S., So, W. Y., Ma, R. C., Kong, A. P., Ozaki, R., Chow, F. C., and Chan, J. C. (2014) Prospective study on the incidences of cardiovascular-renal complications in Chinese patients with young-onset type 1 and type 2 diabetes. *Diabetes Care* **37**, 149-157
55. Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunni, A. K., Awasthi, A., and Dua, K. (2019) Treatment strategies against diabetes: Success so far and challenges ahead. *European journal of pharmacology* **862**, 172625
56. Vijan, S. (2015) In the clinic. Type 2 diabetes. *Ann Intern Med* **162**, ITC1-16
57. Bailey, C. J., and Day, C. (2019) The future of new drugs for diabetes management. *Diabetes Res Clin Pract* **155**, 107785
58. Patti, A. M., Giglio, R. V., Papanas, N., Rizzo, M., and Rizvi, A. A. (2019) Future perspectives of the pharmacological management of diabetic dyslipidemia. *Expert Rev Clin Pharmacol* **12**, 129-143
59. Asrafuzzaman, M., Cao, Y., Afroz, R., Kamato, D., Gray, S., and Little, P. J. (2017) Animal models for assessing the impact of natural products on the aetiology and metabolic pathophysiology of Type 2 diabetes. *Biomedicine & Pharmacotherapy* **89**, 1242-1251
60. Stern, J. H., Rutkowski, J. M., and Scherer, P. E. (2016) Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. *Cell Metab* **23**, 770-784
61. Bronfman, M., Bronfman, F.C., Pinto, C., Pissani C., Paredes Martínes, MJ. . (2014) Method for the preparation of an oleoresin originating from a red alga that maintains the capacity to induce the transcriptional activity of the nuclear receptor PPAR-Gamma. **WO/2014/186913 PCT/CL2013/000031 Pontificia Universidad Católica de Chile**
62. Apak, R., Güçlü, K., Demirata, B., Ozyürek, M., Celik, S. E., Bektaşoğlu, B., Berker, K. I., and Ozyurt, D. (2007) Comparative evaluation of various total antioxidant capacity assays applied to phenolic compounds with the CUPRAC assay. *Molecules* **12**, 1496-1547
63. Fuenzalida, K. M., Aguilera, M. C., Piderit, D. G., Ramos, P. C., Contador, D., Quiñones, V., Rigotti, A., Bronfman, F. C., and Bronfman, M. (2005) Peroxisome proliferator-activated receptor gamma is a novel target of the nerve growth factor signaling pathway in PC12 cells. *J Biol Chem* **280**, 9604-9609
64. Bai, C., Schmidt, A., and Freedman, L. P. (2003) Steroid hormone receptors and drug discovery: therapeutic opportunities and assay designs. *Assay Drug Dev Technol* **1**, 843-852
65. Paguio, A., Stecha, P., Wood, K. V., and Fan, F. (2010) Improved dual-luciferase reporter assays for nuclear receptors. *Curr Chem Genomics* **4**, 43-49
66. Zebisch, K., Voigt, V., Wabitsch, M., and Brandsch, M. (2012) Protocol for effective differentiation of 3T3-L1 cells to adipocytes. *Anal Biochem* **425**, 88-90
67. Kraus, N. A., Ehebauer, F., Zapp, B., Rudolphi, B., Kraus, B. J., and Kraus, D. (2016) Quantitative assessment of adipocyte differentiation in cell culture. *Adipocyte* **5**, 351-358
68. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *Journal of Immunological Methods* **65**, 55-63

69. Almind, K., and Kahn, C. R. (2004) Genetic determinants of energy expenditure and insulin resistance in diet-induced obesity in mice. *Diabetes* **53**, 3274-3285
70. Heydemann, A. (2016) An Overview of Murine High Fat Diet as a Model for Type 2 Diabetes Mellitus. *J Diabetes Res*, 2902351
71. Stiernagle, T. (February 11, 2006 1551-8507) Maintenance of *C. elegans*. *The C. elegans Research Community WormBook WormBook*
72. Minniti, A. N., Arriagada, H., Zúñiga, S., Bravo-Zehnder, M., Alfaro, I. E., and Aldunate, R. (2019) Temporal pattern of neuronal insulin release during *Caenorhabditis elegans* aging: Role of redox homeostasis. *Aging Cell* **18**, e12855
73. Chalfie, M. H., A.C.; Rankin, C.H.; Goddman M.B. (2018) In: WormBook: The Online Review of *C. elegans* Biology [Internet]. Pasadena (CA): WormBook; 2005-2018. <https://www.ncbi.nlm.nih.gov/books/NBK235860/>
74. Possik, E., and Pause, A. (2015) Measuring oxidative stress resistance of *Caenorhabditis elegans* in 96-well microtiter plates. *J Vis Exp*, e52746
75. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., and Evans, R. M. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. *Proc Natl Acad Sci U S A* **91**, 7355-7359
76. Lee, G., Elwood, F., McNally, J., Weiszmam, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., Chen, J. L., and Li, Y. (2002) T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. *J Biol Chem* **277**, 19649-19657
77. Dunn, F. L., Higgins, L. S., Fredrickson, J., and DePaoli, A. M. (2010) Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. *J Diabetes Complications* **25**, 151-158
78. Green, H., and Kehinde, O. (1975) An established preadipose cell line and its differentiation in culture. II. Factors affecting the adipose conversion. *Cell* **5**, 19-27
79. Hu, S., Wang, L., Yang, D., Li, L., Togo, J., Wu, Y., Liu, Q., Li, B., Li, M., Wang, G., Zhang, X., Niu, C., Li, J., Xu, Y., Couper, E., Whittington-Davies, A., Mazidi, M., Luo, L., Wang, S., Douglas, A., and Speakman, J. R. (2018) Dietary Fat, but Not Protein or Carbohydrate, Regulates Energy Intake and Causes Adiposity in Mice. *Cell Metab* **28**, 415-431 e414
80. Toye, A. A., Lippiat, J. D., Proks, P., Shimomura, K., Bentley, L., Hugill, A., Mijat, V., Goldsworthy, M., Moir, L., Haynes, A., Quarterman, J., Freeman, H. C., Ashcroft, F. M., and Cox, R. D. (2005) A genetic and physiological study of impaired glucose homeostasis control in C57BL/6J mice. *Diabetologia* **48**, 675-686
81. Soccio, R. E., Li, Z., Chen, E. R., Foong, Y. H., Benson, K. K., Dispirito, J. R., Mullican, S. E., Emmett, M. J., Briggs, E. R., Peed, L. C., Dzeng, R. K., Medina, C. J., Jolivet, J. F., Kissig, M., Rajapurkar, S. R., Damle, M., Lim, H. W., Won, K. J., Seale, P., Steger, D. J., and Lazar, M. A. (2017) Targeting PPARgamma in the epigenome rescues genetic metabolic defects in mice. *J Clin Invest* **127**, 1451-1462
82. Schubert, N., García-Mendoza, E., Pacheco-Ruiz, Isai. (2006) Carotenoid composition of marine red algae. *j. Phycol.* **42**, 1208-1216

83. Sanz-Pintos, N., Perez-Jimenez, J., Buschmann, A. H., Vergara-Salinas, J. R., Perez-Correa, J. R., and Saura-Calixto, F. Macromolecular Antioxidants and Dietary Fiber in Edible Seaweeds. *J Food Sci* **82**, 289-295
84. Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., and Evans, R. M. (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. *Cell* **83**, 803-812
85. Paniagua-Michel, J., Capa-Robles, W., Olmos-Soto, J., and Gutierrez-Millan, L. E. (2009) The carotenogenesis pathway via the isoprenoid-beta-carotene interference approach in a new strain of *Dunaliella salina* isolated from Baja California Mexico. *Mar Drugs* **7**, 45-56
86. Hosseini, S. M., Khosravi-Darani, K., and Mozafari, M. R. (2013) Nutritional and medical applications of spirulina microalgae. *Mini Rev Med Chem* **13**, 1231-1237
87. Sandoval, V., Femenias, A., Martínez-Garza, Ú., Sanz-Lamora, H., Castagnini, J. M., Quifer-Rada, P., Lamuela-Raventós, R. M., Marrero, P. F., Haro, D., and Relat, J. (2019) Lyophilized Maqui (*Aristotelia chilensis*) Berry Induces Browning in the Subcutaneous White Adipose Tissue and Ameliorates the Insulin Resistance in High Fat Diet-Induced Obese Mice. *Antioxidants* **8**, 360
88. Oh, S. I., Park, J. K., and Park, S. K. (2015) Lifespan extension and increased resistance to environmental stressors by N-acetyl-L-cysteine in *Caenorhabditis elegans*. *Clinics (Sao Paulo)* **70**, 380-386
89. Schulz, T. J., Zarse, K., Voigt, A., Urban, N., Birringer, M., and Ristow, M. (2007) Glucose restriction extends *Caenorhabditis elegans* life span by inducing mitochondrial respiration and increasing oxidative stress. *Cell Metab* **6**, 280-293
90. Hong, F., Pan, S., Guo, Y., Xu, P., and Zhai, Y. (2019) PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. *Molecules* **24**
91. Guasch, L., Sala, E., Mulero, M., Valls, C., Salvado, M. J., Pujadas, G., and Garcia-Vallve, S. Identification of PPARgamma partial agonists of natural origin (II): in silico prediction in natural extracts with known antidiabetic activity. *PLoS One* **8**, e55889
92. Vogl, S., Picker, P., Mihaly-Bison, J., Fakhrudin, N., Atanasov, A. G., Heiss, E. H., Wawrosch, C., Reznicek, G., Dirsch, V. M., Saukel, J., and Kopp, B. (2013) Ethnopharmacological in vitro studies on Austria's folk medicine--an unexplored lore in vitro anti-inflammatory activities of 71 Austrian traditional herbal drugs. *J Ethnopharmacol* **149**, 750-771
93. Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., and Milburn, M. V. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. *Nature* **395**, 137-143
94. Kroker, A. J., and Bruning, J. B. Review of the Structural and Dynamic Mechanisms of PPARgamma Partial Agonism. *PPAR Res* **2015**, 816856
95. Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., and Berkenstam, A. (1998) Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. *J Biol Chem* **273**, 31108-31112
96. Waku, T., Shiraki, T., Oyama, T., Maebara, K., Nakamori, R., and Morikawa, K. The nuclear receptor PPARgamma individually responds to serotonin- and fatty acid-metabolites. *EMBO J* **29**, 3395-3407

97. Dunn, F. L., Higgins, L. S., Fredrickson, J., and DePaoli, A. M. (2011) Selective modulation of PPAR γ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. *J Diabetes Complications* **25**, 151-158
98. Rocchi, S., Picard, F., Vamecq, J., Gelman, L., Potier, N., Zeyer, D., Dubuquoy, L., Bac, P., Champy, M.-F., Plunket, K. D., Leesnitzer, L. M., Blanchard, S. G., Desreumaux, P., Moras, D., Renaud, J.-P., and Auwerx, J. (2001) A Unique PPAR γ Ligand with Potent Insulin-Sensitizing yet Weak Adipogenic Activity. *Molecular Cell* **8**, 737-747
99. Kim, S. N., Choi, H. Y., Lee, W., Park, G. M., Shin, W. S., and Kim, Y. K. (2008) Sargaquinoic acid and sargahydroquinoic acid from *Sargassum yezoense* stimulate adipocyte differentiation through PPAR α /gamma activation in 3T3-L1 cells. *FEBS Lett* **582**, 3465-3472
100. Raskin, P. (2008) Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes. *Diabetes Metab Res Rev* **24**, 3-13
101. Hughes, T. S., Giri, P. K., de Vera, I. M., Marciano, D. P., Kuruvilla, D. S., Shin, Y., Blayo, A. L., Kamenecka, T. M., Burris, T. P., Griffin, P. R., and Kojetin, D. J. An alternate binding site for PPAR γ ligands. *Nat Commun* **5**, 3571
102. Luo, H., Zhou, Y., Hu, X., Peng, X., Wei, H., Peng, J., and Jiang, S. Activation of PPAR γ 2 by PPAR γ 1 through a functional PPRE in transdifferentiation of myoblasts to adipocytes induced by EPA. *Cell Cycle* **14**, 1830-1841
103. Zhao, Y., Calon, F., Julien, C., Winkler, J. W., Petasis, N. A., Lukiw, W. J., and Bazan, N. G. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR γ -mediated mechanisms in Alzheimer's disease models. *PLoS One* **6**, e15816
104. McIntyre, T. M., Pontsler, A. V., Silva, A. R., St Hilaire, A., Xu, Y., Hinshaw, J. C., Zimmerman, G. A., Hama, K., Aoki, J., Arai, H., and Prestwich, G. D. (2003) Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPAR γ agonist. *Proc Natl Acad Sci U S A* **100**, 131-136
105. Tsukahara, T., Tsukahara, R., Yasuda, S., Makarova, N., Valentine, W. J., Allison, P., Yuan, H., Baker, D. L., Li, Z., Bittman, R., Parrill, A., and Tigyi, G. (2006) Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. *J Biol Chem* **281**, 3398-3407
106. Heim, M., Johnson, J., Boess, F., Bendik, I., Weber, P., Hunziker, W., and Fluhmann, B. (2002) Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. *FASEB J* **16**, 718-720
107. Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., and Willett, W. C. (1994) Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. *Diabetes Care* **17**, 961-969
108. Shai, I., Jiang, R., Manson, J. E., Stampfer, M. J., Willett, W. C., Colditz, G. A., and Hu, F. B. (2006) Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. *Diabetes Care* **29**, 1585-1590
109. Choi, J. H., Banks, A. S., Estall, J. L., Kajimura, S., Boström, P., Laznik, D., Ruas, J. L., Chalmers, M. J., Kamenecka, T. M., Blüher, M., Griffin, P. R., and

- Spiegelman, B. M. (2010) Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. *Nature* **466**, 451-456
110. Fu, Y., Luo, N., Klein, R. L., and Garvey, W. T. (2005) Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. *J Lipid Res* **46**, 1369-1379
111. Astapova, O., and Leff, T. (2012) Adiponectin and PPAR γ : cooperative and interdependent actions of two key regulators of metabolism. *Vitam Horm* **90**, 143-162
112. Fang, H., and Judd, R. L. (2018) Adiponectin Regulation and Function. *Compr Physiol* **8**, 1031-1063
113. Mandard, S., Stienstra, R., Escher, P., Tan, N. S., Kim, I., Gonzalez, F. J., Wahli, W., Desvergne, B., Muller, M., and Kersten, S. (2007) Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors. *Cell Mol Life Sci* **64**, 1145-1157
114. Kim, S. Y., Kim, H. I., Park, S. K., Im, S. S., Li, T., Cheon, H. G., and Ahn, Y. H. (2004) Liver glucokinase can be activated by peroxisome proliferator-activated receptor-gamma. *Diabetes* **53 Suppl 1**, S66-70
115. Zhang, Q., Li, N., Liu, X., Zhao, Z., Li, Z., and Xu, Z. (2004) The structure of a sulfated galactan from *Porphyra haitanensis* and its in vivo antioxidant activity. *Carbohydr Res* **339**, 105-111
116. Lin, H.-C. T., Wann-Sheng; Chiu, Tsai-Hsin. (2012) Antioxidant Properties of Seven Cultivated and Natural Edible Seaweed Extracts from Taiwan. *J. Aquat. Food Prod. Technol.* **21**, 248-264
117. Batista-Gonzalez, A., Silva, AM., Vidal-Novoa, A., Pinto, J., Mancini, D., Mancini-Fihlo, J. (2012) Analysis of in vitro and in vivo antioxidant properties of hydrophilic fractions from the seaweed *Halimeda Monile* L. *J. Food Biochem* **36**, 189-197
118. Murakami, A., Ishida, H., Kobo, K., Furukawa, I., Ikeda, Y., Yonaha, M., Aniya, Y., and Ohigashi, H. (2005) Suppressive effects of Okinawan food items on free radical generation from stimulated leukocytes and identification of some active constituents: implications for the prevention of inflammation-associated carcinogenesis. *Asian Pac J Cancer Prev* **6**, 437-448
119. Miranda-Delgado, A. M., MJ.; Paz-Araos, M.; Mellado, M.; Villena, J.; Arancibia, P.; Madrid, A.; Jara-Gutierrez, C. (2018) Antioxidant and anti-cancer activities of brown and red seaweed extracts from Chilean coasts. *Lat. Am. J. Aquat. Res* **46**, 301-313
120. Frankel EN, M., AS. (2000) The problems of using one-dimensional methods to evaluate multifunctional food and biological antioxidants. *J. Sci. Food Agric.* **80**, 16
121. Prior, R. L., Wu, X., and Schaich, K. (2005) Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. *J Agric Food Chem* **53**, 4290-4302
122. Mueller, L., and Boehm, V. (2011) Antioxidant activity of β -carotene compounds in different in vitro assays. *Molecules* **16**, 1055-1069
123. Niki, E., and Traber, M. G. (2012) A history of vitamin E. *Ann Nutr Metab* **61**, 207-212

124. Tsuchihashi, H., Kigoshi, M., Iwatsuki, M., and Niki, E. (1995) Action of beta-carotene as an antioxidant against lipid peroxidation. *Arch Biochem Biophys* **323**, 137-147
125. Corsi, A. K., Wightman, B., and Chalfie, M. (2015) A Transparent window into biology: A primer on *Caenorhabditis elegans*. *WormBook*, 1-31

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Table 1. Fatty acid composition (relative abundance, % over total fatty acids) of *A.chilense oleoresin*.

	Fatty Acid	Chain Length	Mean %	SD
Saturated	Decanoic Acid	10:00	0,760	1,1
	Dodecanoic Acid	12:00	0,305	0,3
	Tridecanoic Acid	13:00	0,983	0,3
	Tetradecanoic Acid	14:00	4,438	0,9
	Pentadecanoic Acid	15:00	0,440	0,3
	Hexadecanoic Acid	16:00	40,005	5,4
	Heptadecanoic Acid	17:00	0,750	1,3
	Octadecanoic Acid	18:00	2,683	3,0
	Eicosanoic Acid	20:00	0,152	0,08
	Docosanoic Acid	22:00	0,238	0,05
	Tetracosanoic Acid	24:00	0,127	0,08
Mono-Insaturated	10-Pentadecaenoic Acid	15:1 n-5	1,87	1,8
	9-Hexadecaenoic Acid	16:1 n-7	0,46	0,3
	9-Octadecaenoic Acid	18:1 n-9	14,13	4,6
	11-Octadecaenoic Acid	18:1 n-7	4,07	1,4
Omega-6 Polyunsaturated	9,12-Octadecadienoic Acid	18:2 n-6	2,87	0,81
	6,9,12-Octadecatrienoic Acid	18:3 n-6	0,17	0,10
	11,14-Eicosadienoic Acid	20:2 n-6	0,34	0,37
	8,11,14-Eicosatrienoic Acid	20:3 n-6	0,47	0,09
	5,8,11,14-Eicosatetraenoic Acid	20:4 n-6	21,06	3,81
Omega-3 Polyunsaturated	9,12,15-Octadecatrienoic Acid	18:3 n-3	0,390	0,42
	5,8,11,14,17-Eicosapentaenoic Acid	20:5 n-3	0,408	0,38
	7,10,13,16,19-Docosapentaenoic Acid	22:5 n-3	0,27	0,12
	4,7,10,13,16,19-Docosahexaenoic Acid	22:6 n-3	0,125	0,04
Other	Conjugated Fatty Acids			
	Fatty Acid	Chain Length	Mean %	SD
	c9, t11-octadecadienoic Acid	18:2 n-cla	0,187	0,06
	Trans Fatty Acids			
	Fatty Acid	Chain Length	Mean %	SD
	10-Transpentadecaenoic Acid	15:1 n-5t	0,258	0,24
	9-Octadecaenoic Acid	18:1 n-9t	1,037	1,30
	11-TransOctadecaenoic Acid	18:1 n-7t	0,540	0,30
	9,12-Octadecadienoic Acid	18:2 n-6tt	0,11	0,04

Fatty acids were detected as methyl fatty acid by GC-FID. Mean of six different lipid extracts produced from independent alga biomass which has been harvested and cultured in different seasons (fall, winter and summer).

Table 2. Total antioxidant capacity (TAC) of *A. chilense oleoresin* and other botanical sources by CUPRAC.

Sample	mg Uric Acid Eq /100mg Oily extract		
	Mean	SD	n
<i>A.chilense</i> oleoresin	430	154,2	7
Spirulina oleoresin	344	156,9	3
Maqui oleoresin	305	86,4	3

Table 3. Antioxidant content characterization of *A.chilense* oleoresin

Antioxidant	µg/g of oleoresin
	Mean ± S.E.M.
α-Tocopherol	527.7 ± 85.3
γ-Tocopherol	5332.8 ± 1523.3
δ-Tocopherol	2660 ± 397.1
Total Tocopherols	6673 ± 1568.2
β-Carotene	1538 ± 378.4

Tocopherol and β-carotene composition in *A.chilense oleoresin*. Value are given as the mean +/- S.E.M (n= 6 independent oleoresin preparations).

Supplementary Figure 1.

Supplementary Figure 2.